On Thursday, Piper Sandler reaffirmed its positive stance on Roivant Sciences (NASDAQ:ROIV), maintaining an Overweight rating and a $22.00 price target for the company's stock.
The endorsement follows a recent key opinion leader (KOL) call regarding Roivant's brepocitinib and its Phase 2 NEPTUNE trial update, which focused on the treatment of non-infectious uveitis (NIU).
The KOL call acted as a supplementary discussion to Piper Sandler's extensive research on NIU and its treatments. The main insight from this conversation was that brepocitinib, assuming it maintains its clinical efficacy into Phase 3 trials, could potentially be utilized in earlier treatment stages. This earlier use could significantly enlarge the drug's market opportunity beyond the firm's current forecasts.
Piper Sandler's analyst highlighted the favorable risk/reward profile of Roivant Sciences' shares and encouraged investors to continue buying up to the $22.00 price target. The firm's confidence is rooted in the potential market expansion for brepocitinib, which is currently anticipated to perform well in ongoing clinical trials.
Roivant Sciences is actively engaged in developing brepocitinib as a treatment option for NIU, a condition that can lead to vision loss if left untreated. The company's focus on this drug is part of a broader portfolio aimed at addressing unmet medical needs through innovative therapies.
The maintained price target and rating reflect Piper Sandler's expectation that Roivant Sciences will continue to present attractive investment opportunities as it progresses through the clinical development of brepocitinib and other potential treatments in its pipeline.
In other recent news, Roivant Sciences has seen significant developments. Financial services firm Piper Sandler raised its price target for Roivant Sciences shares from $20.00 to $22.00 based on promising results from a Phase 2 trial involving Roivant's drug candidate brepocitinib.
The firm's valuation model now includes the potential revenue from brepocitinib's use in treating non-infectious uveitis. Meanwhile, JPMorgan also adjusted its outlook on Roivant Sciences, raising the price target to $16.00, reflecting a positive view of the sales performance of Vtama, a topical cream for plaque psoriasis.
Roivant Sciences' Q4 revenue was reported at $19.3 million, falling slightly short of the expected $22.9 million. Despite this, Piper Sandler reaffirmed its Overweight rating on Roivant, maintaining a stock price target of $20.00, largely attributed to the company's strategic prioritization of their '1402 asset and the growing momentum for brepocitinib.
Roivant's CEO, Matt Gline, has outlined strategic growth plans, emphasizing the expansion of Immunovant (NASDAQ:IMVT)'s portfolio and the launch of VTAMA. The company ended the fiscal year with a robust $6.6 billion in cash and plans to utilize its capital for share repurchases, pipeline investments, and in-licensing new programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.